INT90020

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.75
First Reported 2000
Last Reported 2008
Negated 0
Speculated 0
Reported most in Abstract
Documents 8
Total Number 14
Disease Relevance 1.61
Pain Relevance 8.34

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (SUCLG1) small molecule metabolic process (SUCLG1) plasma membrane (SUCLG1)
ligase activity (SUCLG1) cytoplasm (SUCLG1)
Anatomy Link Frequency
embryonic kidney 1
SUCLG1 (Homo sapiens)
Pain Link Frequency Relevance Heat
opioid receptor 21 99.98 Very High Very High Very High
nalbuphine 7 99.52 Very High Very High Very High
Morphine 25 99.44 Very High Very High Very High
MU agonist 15 99.32 Very High Very High Very High
Buprenorphine 7 99.22 Very High Very High Very High
agonist 72 98.94 Very High Very High Very High
Potency 15 98.14 Very High Very High Very High
antagonist 6 86.08 High High
mu opioid receptor 1 84.44 Quite High
Enkephalin 7 82.60 Quite High
Disease Link Frequency Relevance Heat
Bordatella Infection 11 100.00 Very High Very High Very High
Glioma 8 100.00 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The potency of all the agonists to inhibit forskolin-stimulated adenylyl cyclase was increased in cells expressing RGS-insensitive Galpha(o)(CIGS), Galpha(i2)(CIGS), or Galpha(i3)(CIGS), regardless of efficacy.
Gene_expression (expressing) of Galpha associated with agonist and potency
1) Confidence 0.75 Published 2008 Journal Mol. Pharmacol. Section Abstract Doc Link 18285510 Disease Relevance 0.14 Pain Relevance 0.77
Maximal inhibition of forskolin-stimulated adenylyl cyclase by the low-efficacy partial agonists buprenorphine and nalbuphine was increased in cells expressing RGS-insensitive Galpha(o)(CIGS), Galpha(i2)(CIGS), or Galpha(i3)(CIGS) compared with their Galpha(CI) counterparts, but the RGS-insensitive mutation had little or no effect on the maximal inhibition by the higher efficacy agonists DAMGO and morphine.
Gene_expression (expressing) of Galpha associated with nalbuphine, agonist, morphine and buprenorphine
2) Confidence 0.75 Published 2008 Journal Mol. Pharmacol. Section Abstract Doc Link 18285510 Disease Relevance 0.17 Pain Relevance 0.71
The potency of all the agonists to inhibit forskolin-stimulated adenylyl cyclase was increased in cells expressing RGS-insensitive Galpha(o)(CIGS), Galpha(i2)(CIGS), or Galpha(i3)(CIGS), regardless of efficacy.
Gene_expression (expressing) of Galpha associated with agonist and potency
3) Confidence 0.75 Published 2008 Journal Mol. Pharmacol. Section Abstract Doc Link 18285510 Disease Relevance 0.14 Pain Relevance 0.77
The potency of all the agonists to inhibit forskolin-stimulated adenylyl cyclase was increased in cells expressing RGS-insensitive Galpha(o)(CIGS), Galpha(i2)(CIGS), or Galpha(i3)(CIGS), regardless of efficacy.
Gene_expression (expressing) of Galpha associated with agonist and potency
4) Confidence 0.75 Published 2008 Journal Mol. Pharmacol. Section Abstract Doc Link 18285510 Disease Relevance 0.14 Pain Relevance 0.77
Maximal inhibition of forskolin-stimulated adenylyl cyclase by the low-efficacy partial agonists buprenorphine and nalbuphine was increased in cells expressing RGS-insensitive Galpha(o)(CIGS), Galpha(i2)(CIGS), or Galpha(i3)(CIGS) compared with their Galpha(CI) counterparts, but the RGS-insensitive mutation had little or no effect on the maximal inhibition by the higher efficacy agonists DAMGO and morphine.
Gene_expression (expressing) of Galpha associated with nalbuphine, agonist, morphine and buprenorphine
5) Confidence 0.75 Published 2008 Journal Mol. Pharmacol. Section Abstract Doc Link 18285510 Disease Relevance 0.17 Pain Relevance 0.71
To determine the role of endogenous RGS proteins in functional responses to mu-opioid agonists of different intrinsic efficacy, Galpha(i/o) subunits with a mutation at the pertussis toxin (PTX)-sensitive cysteine (C351I) and with or without a mutation at the RGS binding site (G184S) were stably expressed in C6 glioma cells expressing a mu-opioid receptor.
Gene_expression (expressed) of Galpha associated with mu agonist, bordatella infection, opioid receptor and glioma
6) Confidence 0.65 Published 2008 Journal Mol. Pharmacol. Section Abstract Doc Link 18285510 Disease Relevance 0.20 Pain Relevance 0.62
Maximal inhibition of forskolin-stimulated adenylyl cyclase by the low-efficacy partial agonists buprenorphine and nalbuphine was increased in cells expressing RGS-insensitive Galpha(o)(CIGS), Galpha(i2)(CIGS), or Galpha(i3)(CIGS) compared with their Galpha(CI) counterparts, but the RGS-insensitive mutation had little or no effect on the maximal inhibition by the higher efficacy agonists DAMGO and morphine.
Gene_expression (expressing) of Galpha associated with nalbuphine, agonist, morphine and buprenorphine
7) Confidence 0.65 Published 2008 Journal Mol. Pharmacol. Section Abstract Doc Link 18285510 Disease Relevance 0.17 Pain Relevance 0.71
Coupling efficacy and selectivity of the human mu-opioid receptor expressed as receptor-Galpha fusion proteins in Escherichia coli.
Gene_expression (expressed) of Galpha associated with opioid receptor
8) Confidence 0.10 Published 2000 Journal J. Neurochem. Section Title Doc Link 10936202 Disease Relevance 0 Pain Relevance 0.54
Galpha , G , G or G were individually transiently transfected into C6 glioma cells stably expressing the mu-opioid receptor, or transiently co-expressed with the mu-opioid receptor into human embryonic kidney (HEK)293T cells.
Gene_expression (expressing) of Galpha in embryonic kidney associated with opioid receptor and glioma
9) Confidence 0.09 Published 2006 Journal J. Neurochem. Section Abstract Doc Link 17230639 Disease Relevance 0.46 Pain Relevance 0.33
Two constructs encoding the human micro-opioid receptor (hMOR) fused at its C terminus to either one of two Galpha subunits, Galpha(o1) (hMOR-Galpha(o1)) and Galpha(i2) (hMOR-Galpha(i2)), were expressed in Escherichia coli at levels suitable for pharmacological studies (0.4-0.5 pmol/mg).
Gene_expression (one) of Galpha associated with opioid receptor
10) Confidence 0.08 Published 2000 Journal J. Neurochem. Section Abstract Doc Link 10936202 Disease Relevance 0 Pain Relevance 0.31
Two constructs encoding the human micro-opioid receptor (hMOR) fused at its C terminus to either one of two Galpha subunits, Galpha(o1) (hMOR-Galpha(o1)) and Galpha(i2) (hMOR-Galpha(i2)), were expressed in Escherichia coli at levels suitable for pharmacological studies (0.4-0.5 pmol/mg).
Gene_expression (one) of Galpha associated with opioid receptor
11) Confidence 0.07 Published 2000 Journal J. Neurochem. Section Abstract Doc Link 10936202 Disease Relevance 0 Pain Relevance 0.38
In the presence of Gbetagamma dimers, the affinities of DAMGO and endomorphin-1 and -2 were higher at hMOR-Galpha(i2) than at hMOR-Galpha(o1), whereas morphine displayed similar affinities at the two chimeras.
Gene_expression (higher) of Galpha associated with morphine
12) Confidence 0.07 Published 2000 Journal J. Neurochem. Section Abstract Doc Link 10936202 Disease Relevance 0 Pain Relevance 0.67
Two constructs encoding the human micro-opioid receptor (hMOR) fused at its C terminus to either one of two Galpha subunits, Galpha(o1) (hMOR-Galpha(o1)) and Galpha(i2) (hMOR-Galpha(i2)), were expressed in Escherichia coli at levels suitable for pharmacological studies (0.4-0.5 pmol/mg).
Gene_expression (expressed) of Galpha associated with opioid receptor
13) Confidence 0.07 Published 2000 Journal J. Neurochem. Section Abstract Doc Link 10936202 Disease Relevance 0 Pain Relevance 0.38
In the presence of Gbetagamma dimers, the affinities of DAMGO and endomorphin-1 and -2 were higher at hMOR-Galpha(i2) than at hMOR-Galpha(o1), whereas morphine displayed similar affinities at the two chimeras.
Gene_expression (higher) of Galpha associated with morphine
14) Confidence 0.07 Published 2000 Journal J. Neurochem. Section Abstract Doc Link 10936202 Disease Relevance 0 Pain Relevance 0.67

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox